Article
Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients
3 Feb 2011
Abstract excerpt
Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disease primarily affecting motor neurons. We recently identified intermediate-length polyglutamine (polyQ) expansions (27-33 Qs) in ataxin 2 as a genetic risk factor for sporadic ALS in North American ALS patients. To extend these findings, we assessed the ataxin 2 polyQ repeat length in 1294 European ALS patients and 679 matched...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
